BRG Managing Director Dan Troy Honored as Top 20 Innovative General Counsel by Financial Times

BRG today announced that Managing Director Dan Troy received the “20 Years of Innovative Lawyers: 20 General Counsel” honor at the Financial Times’ Innovative Lawyers Global Summit for his creative legal work over the past two decades, including his efforts to remove the billable hour.

A globally recognized thought leader, Troy was previously honored by the Financial Times in 2016 as one of 30 global general counsel awardees and named a “Legend of Law” at the 2013 Burton Awards. Throughout his career, he has combined his extensive legal, technical and business expertise to deliver uniquely successful results on behalf of clients, corporations and government agencies.

“I’m gracious to have received recognition for some of the work that has been most meaningful to me and the broader legal community and to have been honored alongside prestigious minds,” Troy said. “My tenure over the last few decades guides how I counsel clients every day at BRG.”

Troy previously served as the Food and Drug Administration’s (FDA) chief counsel and spent a decade as general counsel and senior vice president of GSK plc. Troy was also a partner at preeminent law firms Sidley Austin LLP and Wiley Rein LLP, where he advised leading multinational healthcare companies.

As a member of BRG’s Health Analytics practice, Troy works with law firms and pharmaceutical companies to provide expert witness testimony on FDA regulation, healthcare policy and related matters. He leverages his breadth of knowledge and experience to provide valuable insights to clients navigating high-profile, complex compliance and business issues with an understanding of the pressures facing in-house and outside counsel.

“No one knows the FDA better than Dan. In his more than 30-year career, he has helped shape pharmaceutical regulatory matters for life sciences companies, law firms and the government alike,” said Jerry Lewandowski, a managing director in BRG’s Health Analytics practice. “This is a well-deserved acknowledgement of Dan’s decades pioneering the field.”

At the FDA, Troy was a primary liaison to the White House and the Department of Health and Human Services. He spearheaded initiatives on Hatch-Waxman reform, First Amendment preemption and Securities and Exchange Commission (SEC)–FDA interactions. Additionally, he oversaw the FDA’s litigation and enforcement efforts and helped shape major regulations and guidance.

As general counsel at GSK, Troy resolved numerous high-profile investigations from the Department of Justice, including those related to the Foreign Corrupt Practices Act. Troy also chaired the US Chamber of Commerce Litigation Center and lead committees and sections within PhRMA, the American Bar Association and the American Law Institute.

This year’s FT Innovative Lawyers Global Summit brought together legal leaders to reflect on lessons learned in the past 20 years of legal innovation. A selection of over 250 of the most elite alumni of the FT awards program were invited to attend the summit to celebrate the 20 honorees.